Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05541250 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI)
A Phase 1 study of Peripheral Nerve Injury, sponsored by W. Dalton Dietrich.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05541250 is a Phase 1 study of Peripheral Nerve Injury that is actively recruiting participants, run by W. Dalton Dietrich. The registered enrollment target is 30 participants, roughly in line with the 33-participant average among 3 other Peripheral Nerve Injury trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT05541250, a Phase 1 study of Peripheral Nerve Injury, is actively recruiting participants, sponsored by W. Dalton Dietrich.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this research study is to evaluate the safety and possible harms of injecting one's own Schwann cells along with nerve auto-graft after a severe injury to a major nerve has occurred.
Conditions Studied
Interventions
- BIOLOGICAL Autologous Human Schwann Cell
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2026-09-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05541250
The ClinicalTrials.gov registry entry for NCT05541250 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 33-participant average among 3 other Peripheral Nerve Injury trials with a reported enrollment target. The listed sponsor is W. Dalton Dietrich, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Nerve Injury appearing as the primary indexed condition, and to 1 intervention - of which Autologous Human Schwann Cell is the first listed.
NCT05541250 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05541250 about?
NCT05541250 is a clinical study titled "Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI)". The primary purpose of this research study is to evaluate the safety and possible harms of injecting one's own Schwann cells along with nerve auto-graft after a severe injury to a major nerve has occurred.
What is the current status of trial NCT05541250?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-05-04. Estimated completion is 2026-09-29.
What conditions does trial NCT05541250 study?
This clinical trial studies the following conditions: Peripheral Nerve Injury.
What interventions are being tested in trial NCT05541250?
The interventions under investigation include: Autologous Human Schwann Cell (BIOLOGICAL).
Who is sponsoring clinical trial NCT05541250?
This trial is sponsored by W. Dalton Dietrich, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05541250 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Nerve Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
RECRUITING · Phase 1
-
4-AP Peripheral Nerve Crossover Trial
RECRUITING · Phase 2
-
Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.